Migraine pain relief in as little as 10 minutes
Some patients experience migraine pain relief in as little as 10 minutes with just one spray (13% vs. 5% for placebo).*1-3
Efficacy of Tosymra is based on relative bioavailability to subcutaneous sumatriptan at a dose of 4 mg. In a clinical study, this dose of sumatriptan resulted in 57% of patients achieving pain relief at 2 hours vs. 21% for placebo.
*Time to onset and degree of pain relief varies by patient.Learn More
Tosymra for free†
Commercially insured patients pay $0† per prescription, regardless of coverage, only through our pharmacy partner, Blink Pharmacy Plus.
†Restrictions apply. Filling prescription through Blink Pharmacy Plus required. Maximum of eight single-dose nasal spray units per month. Medicare, Medicaid, and other federal and state healthcare program patients are not eligible.
- Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
- Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
- Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.